Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.66 |
| ▸ | LCK | P06239 | 4/20 | 0.55 |
| ▸ | CSF1R | P07333 | 4/20 | 0.55 |
| ▸ | DRD2 | P14416 | 7/20 | 0.51 |
| ▸ | DRD3 | P35462 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4702294 | 0.95 | MAPK14 (0.68) | MAPK14LCKCSF1RDRD2DRD3 | |
| SCHEMBL4701563 | 0.92 | MAPK14 (0.63) | MAPK14LCKCSF1RDRD2DRD3 | |
| SCHEMBL4818830 | 0.87 | MAPK14 (0.72) | MAPK14KMT2A | |
| SCHEMBL4812867 | 0.86 | MAPK14 (0.71) | MAPK14KMT2A | |
| SCHEMBL4700691 | 0.85 | MAPK14 (0.65) | MAPK14LCKCSF1RKMT2AEGFR | |
| SCHEMBL4820863 | 0.85 | MAPK14 (0.74) | MAPK14KMT2A | |
| SCHEMBL4701759 | 0.83 | MAPK14 (0.60) | MAPK14KMT2A | |
| SCHEMBL4820018 | 0.83 | MAPK14 (0.67) | MAPK14KMT2A | |
| SCHEMBL4700921 | 0.83 | LCK (0.63) | MAPK14LCKCSF1REGFRKDR | |
| SCHEMBL4700702 | 0.82 | MAPK14 (0.64) | MAPK14LCKCSF1RKMT2AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436272-B1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-05-07 | — | — | EP | claimed |
| US-7309800-B2 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-12-18 | — | — | US | claimed |
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-10 | — | — | US | claimed |
| US-7151118-B2 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-12-19 | — | — | US | claimed |
| EP-1436272-B1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-05-07 | — | — | EP | disclosed |
| US-7309800-B2 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-7151118-B2 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-12-19 | — | — | US | disclosed |
| US-20050020540-A1 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK3 | MAPK14 6/4885LCK 61/4885CSF1R 1973/4885 |
| US-20050020540-A1 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | MAPK1, MAPKAPK2, MAP3K1 | MAPK14 32/4885LCK 91/4885CSF1R 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.